Polaris Group’s lead product candidate, ADI-PEG 20 receives US and EU orphan designations

Polaris Group’s lead product candidate, ADI-PEG 20 (pegylated arginine deiminase), received orphan drug designations for the treatment of malignant pleural mesothelioma in the U.S. and the European Union.

Having completed a successful randomized phase II trial in argininosuccinate synthetase -deficient MPM patients with ADI-PEG 20 as monotherapy, Polaris is currently conducting a phase 1 trial of ADI-PEG 20 in combination with pemetrexed and cisplatin, the approved first-line treatment for MPM, for the treatment of MPM and non-squamous non-small cell lung carcinoma.

Polaris is also conducting clinical trials on ADI-PEG 20 both as monotherapy and in combination with other agents, for the treatment of several other indications including breast cancer, melanomas, ovarian cancer and hepatocellular carcinoma.

ADI-PEG 20 is designed to deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed.

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Podcast

“There is no safe harbor:” FY26 funding bill collapses after ICE shooting of Alex Pretti

In last week’s issue of The Cancer Letter, Jacquelyn Cobb, associate editor, wrote a story about the then-promising legislative package that was passed by the U.S. House of Representatives Jan. 22. At the time, the package was expected to pass in the Senate, provide funding for the federal government through fiscal year 2026, and prevent a government shutdown that looms Jan. 30.

January 28, 2026

Vol.52 No.03

Clinical

Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer

A story is told that after first obtaining approval for marketing Premarin in 1942, Wyeth Laboratories didn’t lock up the secret recipe for making the hormonal drug in a company safe, to be guarded by patent lawyers.

January 23, 2026

Vol.52 No.03

By Claire Marie Porter

Capitol Hill

Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched

The U.S. House of Representatives Jan. 22 passed a three-bill minibus package that is expected to be the grand finale of the drama of the fiscal year 2026 appropriations process. The package, which funds the HHS as well as the departments of Defense, Transportation, Housing and Urban Development, Labor, and Education, gives NIH and NCI modest raises over FY25, and nullifies several aggressive cuts the White House had proposed for NIH.

Fifth time’s a charm? Mikaela Naylon Give Kids a Chance Act is included in FY26 spending bill

Sometime next week, the Senate is expected to vote on a legislative package that would determine the fiscal year 2026 spending levels for much of the federal government. xxx:moreReaders of The Cancer Letter may be breathing a sigh of relief that NIH seems like

Blood Cancer United: A new name at the right moment

This past summer, the organization I lead, formerly known as The Leukemia & Lymphoma Society, announced our new name: Blood Cancer United. It reflects our ongoing commitment to the entire blood cancer community—patients, families, caregivers, researchers, healthcare professionals, and partners—and our work to advance progress for those impacted by all types of blood cancer.

January 23, 2026

Vol.52 No.03

By E. Anders Kolb

Opening doors to immunotherapy in prostate cancer: A roadmap from clinic to community

Prostate cancer remains a formidable challenge, particularly in its advanced stages, where bone metastases and treatment resistance dominate outcomes. At City of Hope, our focus is on leveraging immunotherapy to transform this landscape.

January 23, 2026

Vol.52 No.03

By Tanya Dorff

Polaris Group’s lead product candidate, ADI-PEG 20 receives US and EU orphan designations

YOU MAY BE INTERESTED IN

“There is no safe harbor:” FY26 funding bill collapses after ICE shooting of Alex Pretti

Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer

Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched

Fifth time’s a charm? Mikaela Naylon Give Kids a Chance Act is included in FY26 spending bill

Blood Cancer United: A new name at the right moment

Opening doors to immunotherapy in prostate cancer: A roadmap from clinic to community

Renew today!

Subscriber content

Never miss an issue!

Login

Polaris Group’s lead product candidate, ADI-PEG 20 receives US and EU orphan designations

YOU MAY BE INTERESTED IN

“There is no safe harbor:” FY26 funding bill collapses after ICE shooting of Alex Pretti

Premarin’s 84-year hold on the market ends as FDA approves a generic versionTrade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer

Spending bill passed by the House gives NIH $415M raise, NCI gets $128MLegislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched

Fifth time’s a charm? Mikaela Naylon Give Kids a Chance Act is included in FY26 spending bill

Blood Cancer United: A new name at the right moment

Opening doors to immunotherapy in prostate cancer: A roadmap from clinic to community

Never miss an issue!

Login

Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer

Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched